Cabergoline Effect on Blood Sugar in Type 2 Diabetics
Information source: Mashhad University of Medical Sciences
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Type 2
Intervention: Cabergoline (Drug)
Status: Not yet recruiting
Sponsored by: Mashhad University of Medical Sciences
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months
and their blood glucose is evaluated.
Official title: Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: FBS (fasting blood sugar)
Secondary outcome: HbA1C
Minimum age: N/A.
Maximum age: N/A.
- Type 2 diabetes
- Psychiatric disorders
Locations and Contacts
Starting date: January 2012
Last updated: October 24, 2011